Accelerate Diagnostics, Inc.

As of August 3, 2017, Accelerate Diagnostics, Inc. is considered risky and overvalued due to negative valuation ratios and a year-to-date return of -100.0%, significantly underperforming the S&P 500's 12.22% return.

As of June 17, 2025, the market trend is mildly bearish with weak indicators, showing mixed signals from MACD and RSI, while Dow Theory confirms a bearish outlook on the monthly chart.

As of August 3, 2017, Accelerate Diagnostics, Inc. is classified as risky and overvalued due to its negative P/E ratio, a price to book value of -0.01, and an EV to EBITDA of -1.51, with a year-to-date return of -99.53% compared to the S&P 500's 2.44%.

As of March 2022, the management team of Accelerate Diagnostics, Inc. includes Mr. John Patience (Independent Chairman), Mr. John Phillips (CEO and COO), and several Independent Directors: Mr. Thomas Brown, Mr. Roland Diggelmann, Ms. Louise Francesconi, Mr. Mark Miller, and Mr. Jack Schuler. They are responsible for the company's strategic direction and operations.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company focused on improving patient outcomes through the diagnosis of serious infections. As of December 2024, it reported net sales of $3 million and a net loss of $10 million, with a market cap of $0.22 million.

As of Jun 18, Accelerate Diagnostics, Inc. has a market capitalization of $0.22 million, with net sales of $11.71 million and a net profit of -$50.05 million over the last four quarters. Shareholder's funds are reported at -$56.04 million, and total assets amount to $28.56 million.